SCHEMBL247360

SCHEMBL247360

O=C(c1cccc2ccccc12)c1ccc(OS(=O)(=O)C(F)(F)F)c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 13/20 0.55
CNR1 P21554 9/20 0.55
CYP2C9 P11712 1/20 0.52
CDC25B P30305 3/20 0.50
NR4A1 P22736 1/20 0.44
NR4A2 P43354 1/20 0.44
NR4A3 Q92570 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
BCL2 P10415 1/20 0.40
MCL1 Q07820 1/20 0.40
BAD Q92934 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29937164 0.80 ALDH1A1 (0.46) KMT2AMEN1HTTTDP1L3MBTL1
SCHEMBL1056365 0.80 ALDH1A1 (0.46) KMT2AMEN1HTTTDP1L3MBTL1
SCHEMBL6851155 0.80 MEN1 (0.38) KMT2AMEN1GAA
SCHEMBL4467822 0.78 PLK1 (0.44) CDC25BNR4A2KMT2AMEN1MAPT
Hydrogen Sulfide SCHEMBL27507715 0.78 ALDH1A1 (0.45) KMT2AMEN1HTTTDP1L3MBTL1
SCHEMBL2649939 0.77 PLK1 (0.43) CNR2CNR1CYP2C9CDC25BKMT2A
SCHEMBL249407 0.77 CNR2 (0.67) CNR2CNR1CYP2C9
SCHEMBL1902043 0.77 ELANE (0.46) CYP2C9KMT2AMEN1MAPTTDP1
SCHEMBL203899 0.76 MEN1 (0.42) KMT2AMEN1GAA
SCHEMBL29706003 0.76 MEN1 (0.42) KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 US disclosed
US-20040053890-A1 Naphthalene derivatives NOVARTIS AG (CH) 2004-03-18 US disclosed
EP-1339663-A2 NAPHTHALENE DERIVATIVES Novartis AG (CH) 2003-09-03 EP disclosed
WO-2002042248-A2 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053890-A1 Naphthalene derivatives CYP1A1, SULT1E1, CYP2F1 CNR2 86/4885CNR1 35/4885CYP2C9 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.